Active substance
Triptorelin
- SFDA 7
- US FDA 4
- Health Canada 4
- NHS prices 4
- WHO EML 1
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DECAPEPTYL 0.1MG S.C. Injection* | 0.1 mg | Solution for injection · Subcutaneous use | 7 Pre-filled syringe | SAR 211.45 | NCE · Prescription | FERRING | Valid |
| DECAPEPTYL CR 3.75MG SYRINGE | 3.75 mg | Powder and solvent for suspension for injection · Intramuscular use | 1 Pre-filled syringe | SAR 527.05 | NCE · Prescription | FERRING | Valid |
| DIPHERELINE 0.1 MG POWDER FOR SOLUTION FOR INJECTION / INFUSION | 0.1 mg | powder for solution for injection · Subcutaneous use | 7 Vial | SAR 122.80 | NCE · Prescription | IPSEN PHARMA | Valid |
| DIPHERELINE P.R. 11.25 mg Powder for Suspension for Injection | 11.25 mg | Powder and solvent for suspension for injection · Intramuscular use | 1 Vial | SAR 1204.00 | NCE · Prescription | IPSEN PHARMA | Valid |
| DIPHERELINE P.R. 3 mg Powder for Suspension for Injection | 3 mg | Powder and solvent for suspension for injection · Intramuscular use | 1 Vial | SAR 458.35 | NCE · Prescription | IPSEN PHARMA | Valid |
| Diphereline P.R. | 22.5 mg | Powder and solvent for suspension for injection · Intramuscular use | 1 Vial | SAR 2350.20 | NCE · Prescription | IPSEN PHARMA | Valid |
| DECAPEPTYL DEPOT NOVUM 3.75MG VIAL+SOLVT | 3.75 mg | Solution · Intramuscular use | 1 Vial | SAR 699.65 | NCE · Prescription | FERRING | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
MENSTRUAL DISORDERS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TRELSTAR | EQ 3.75MG BASE/VIAL | injectable · intramuscular | VERITY | Prescription | 15 Jun 2000 |
| TRELSTAR | EQ 11.25MG BASE/VIAL | injectable · intramuscular | VERITY | Prescription | 29 Jun 2001 |
| TRELSTAR | EQ 22.5MG BASE/VIAL | injectable · intramuscular | VERITY | Prescription | 10 Mar 2010 |
| TRIPTODUR KIT | EQ 22.5MG BASE/VIAL | for suspension, extended release · intramuscular | AZURITY | Prescription | 29 Jun 2017 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DECAPEPTYL | 02389282 | 0.1 MG / ML | SOLUTION · SUBCUTANEOUS | FERRING INC |
| TRELSTAR | 02240000 | 3.75 MG / VIAL | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | KNIGHT THERAPEUTICS INC. |
| TRELSTAR | 02243856 | 11.25 MG / VIAL | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | KNIGHT THERAPEUTICS INC. |
| TRELSTAR | 02412322 | 22.5 MG / VIAL | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | KNIGHT THERAPEUTICS INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Triptorelin 11.25mg powder and solvent for prolonged-release suspension for injection vials | £207.00 | 1 vial | 1 Oct 2026 |
| NHS Drug Tariff | Triptorelin acetate 3.75mg powder and solvent for prolonged-release suspension for injection pre-filled syringes | £81.69 | 1 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Triptorelin acetate 3mg powder and solvent for prolonged-release suspension for injection vials | £69.00 | 1 vial | 1 Oct 2026 |
| NHS Drug Tariff | Triptorelin embonate 22.5mg powder and solvent for prolonged-release suspension for injection vials | £414.00 | 1 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.2.4. Hormones and antihormones · complementary
Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast; Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
Safety signals and safety-related labeling changes
- US FDA 26 Jun 2026 TRELSTAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Jun 2026 TRELSTAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Jun 2026 TRELSTAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Sep 2025 TRIPTODUR KIT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 29 Sep 2017 PRAC signal: Thromboembolic events
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.